Hepatobiliary Diagnostic Procedures without CC/MCC DRG Reimbursement

DRG 422 encompasses inpatient admissions for hepatobiliary diagnostic procedures without Complication or Comorbidity and without Major Complication or Comorbidity, including diagnostic biliary and hepatic interventions. This Diagnosis-Related Group matters for inpatient reimbursement because it groups cases with comparable resource use to determine Medicare payment rates for the stay.

DRG 422 Overview

DRG 422 covers hospital inpatient stays for patients undergoing hepatobiliary diagnostic procedures without a Complication or Comorbidity and without a Major Complication or Comorbidity. Typical services include diagnostic imaging and invasive biliary or hepatic diagnostic interventions performed for evaluation rather than definitive therapeutic intent. This Diagnosis-Related Group groups cases with similar resource use to determine Medicare inpatient payment relative to other categories. Accurate coding of diagnoses and procedures is essential because classification into this Diagnosis-Related Group affects reimbursement levels for the admission.

Studies evaluating diagnostic accuracy and safety of advanced hepatobiliary imaging and endoscopic procedures: Trials focus on comparing modalities such as specialized MRI sequences, contrast-enhanced ultrasound, and endoscopic retrograde cholangiopancreatography (ERCP) with diagnostic cholangiography in patients admitted for unexplained jaundice, biliary obstruction, or suspected bile duct injury. The patient population includes adults undergoing inpatient diagnostic hepatobiliary workup without major comorbid complications (no CC/MCC), and outcomes measured include diagnostic yield, need for subsequent therapeutic procedures, complication rates (e.g., pancreatitis, bleeding), and length of stay. This research is relevant to providers and payers because better diagnostic pathways can reduce unnecessary procedures, minimize complications that drive higher costs, and optimize resource use within the DRG payment bundle.
Comparative effectiveness trials of pre-procedural risk stratification and pathway implementation: These studies test clinical decision support tools, predictive scoring systems, or standardized pre-procedure checklists to triage which inpatients with liver function abnormalities or biliary pain require invasive diagnostic procedures versus observation and noninvasive testing. Target populations are hospitalized patients without major comorbidities where the clinical question is whether targeted pathways reduce procedure utilization, hospital length of stay, and downstream diagnostic redundancy. For clinicians and payers, validated risk stratification can lower procedure-related complications and readmissions and ensure appropriate use of the DRG’s bundled reimbursement by aligning care intensity with patient risk.
Post-discharge outcomes and health services research assessing downstream resource use after hepatobiliary diagnostic admissions: Observational cohort studies examine rates of subsequent therapeutic interventions, readmissions for biliary disease, outpatient follow-up adherence, and patient-reported outcomes in patients discharged after inpatient diagnostic hepatobiliary procedures without CC/MCC. The population includes patients receiving diagnostic-only admissions to capture real-world trajectories, including delayed identification of tumors, need for elective surgery, or recurrent biliary events. Findings inform payers and health systems about long-term costs, timing of follow-up care, and opportunities to redesign discharge planning to prevent costly downstream utilization and improve value within the DRG framework.

Studies evaluating diagnostic accuracy and safety of advanced hepatobiliary imaging and endoscopic procedures: Trials focus on comparing modalities such as specialized MRI sequences, contrast-enhanced ultrasound, and endoscopic retrograde cholangiopancreatography (ERCP) with diagnostic cholangiography in patients admitted for unexplained jaundice, biliary obstruction, or suspected bile duct injury. The patient population includes adults undergoing inpatient diagnostic hepatobiliary workup without major comorbid complications (no CC/MCC), and outcomes measured include diagnostic yield, need for subsequent therapeutic procedures, complication rates (e.g., pancreatitis, bleeding), and length of stay. This research is relevant to providers and payers because better diagnostic pathways can reduce unnecessary procedures, minimize complications that drive higher costs, and optimize resource use within the DRG payment bundle.
Comparative effectiveness trials of pre-procedural risk stratification and pathway implementation: These studies test clinical decision support tools, predictive scoring systems, or standardized pre-procedure checklists to triage which inpatients with liver function abnormalities or biliary pain require invasive diagnostic procedures versus observation and noninvasive testing. Target populations are hospitalized patients without major comorbidities where the clinical question is whether targeted pathways reduce procedure utilization, hospital length of stay, and downstream diagnostic redundancy. For clinicians and payers, validated risk stratification can lower procedure-related complications and readmissions and ensure appropriate use of the DRG’s bundled reimbursement by aligning care intensity with patient risk.
Post-discharge outcomes and health services research assessing downstream resource use after hepatobiliary diagnostic admissions: Observational cohort studies examine rates of subsequent therapeutic interventions, readmissions for biliary disease, outpatient follow-up adherence, and patient-reported outcomes in patients discharged after inpatient diagnostic hepatobiliary procedures without CC/MCC. The population includes patients receiving diagnostic-only admissions to capture real-world trajectories, including delayed identification of tumors, need for elective surgery, or recurrent biliary events. Findings inform payers and health systems about long-term costs, timing of follow-up care, and opportunities to redesign discharge planning to prevent costly downstream utilization and improve value within the DRG framework.

OpenPayer

Summary & Overview

Hepatobiliary Diagnostic Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 422 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes